Non-invasive prenatal detection of ocutaneous albinism type I based on cfDNA barcode-enabled single-molecule test.
10.3760/cma.j.cn511374-20200214-00077
- Author:
Conghui WANG
1
;
Chen CHEN
;
Xiaofeng WANG
;
Xuechao ZHAO
;
Ganye ZHAO
;
Li'na LIU
;
Xiangdong KONG
Author Information
1. Center of Genetic and Prenatal Diagnosis, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450002, China. kongxdtougao@163.com.
- Publication Type:Journal Article
- MeSH:
Albinism;
Albinism, Oculocutaneous/genetics*;
Amniocentesis;
Cell-Free Nucleic Acids;
Female;
Humans;
Pregnancy;
Prenatal Diagnosis
- From:
Chinese Journal of Medical Genetics
2021;38(4):317-320
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To assess the value of non-invasive prenatal testing based on cfDNA barcode-enabled single-molecule test (cfBEST) for the prenatal diagnosis of oculocutaneous albinism type I in a family.
METHODS:Prenatal genetic diagnosis was carried out by using the cfBEST-based method as well as invasive prenatal diagnosis through amniocentesis. The outcome of the pregnancy was followed up.
RESULTS:Non-invasive prenatal testing based on cfBEST showed a fetal DNA concentration of 6.6%, with the proportion of c.929_930insC (p.Arg311Lysfs*7) and c.1037-7T>A mutations being 45.7% and 0%, respectively. The posterior frequency of the negative results was 1, suggesting that the fetus carried neither of the two mutations. The result was consistent with that of invasive prenatal diagnosis, and the follow-up found that the fetus was normal.
CONCLUSION:Non-invasive prenatal testing based on cfBEST can be used to detect maternal and fetal genotypes in maternal cell-free DNA, which is clinically feasible.
